U.K.-based GW Pharmaceuticals (“GW Pharma”) was formed in 1998 to develop cannabinoid based drugs. Much of its research and development efforts are focused on treatments for rare conditions stemming from epilepsy, glioma (a form of brain tumor), and schizophrenia.

You must subscribe to Cannabis Investor’s Report Lifetime to view this content.

To learn more and access special member pricing contact our VIP team at 1-866-298-7257. 

Sign In

Enter your details below.